What is Rybelsus
Rybelsus is a medicine with the active ingredient semaglutide in tablet form from pharmaceutical company Novo Nordisk. It is registered for the treatment of adults with type 2 diabetes mellitus, when diet and exercise alone are not sufficient to control blood sugar. Within The Body Clinic, a doctor assesses during the consultation whether treatment with medication is suitable within a medical trajectory. More information about our medical approach can be found in our treatment program
Dosage build-up
Treatment with Rybelsus starts with a low dose of 1.5 mg per day. The dose can then be increased step by step, depending on the effect and how well you tolerate the medication. There is at least one month between two dose increases. When the dose is increased every month, the build-up looks like this:
| Month | Dose once a day |
|---|---|
| Month 1 | 1.5 mg |
| Month 2 | 4 mg |
| Month 3 | 9 mg |
| Month 4 | 25 mg |
The starting dose of 1.5 mg is intended to let your body get used to the medication. The maximum dose is 25 mg per day. Your doctor will assess which dose is right for you.
Semaglutide (oral)
Semaglutide is a GLP-1 receptor agonist. It stimulates insulin release when blood sugar rises and inhibits glucagon release. This leads to better blood sugar regulation. In oral form (Rybelsus), semaglutide is taken daily as a tablet. Its absorption in the body depends on the correct timing of intake.
Rybelsus for Type 2 Diabetes
Rybelsus is used as an adjunct to diet and exercise in adults with type 2 diabetes mellitus. The goal of treatment is to improve glycemic control and reduce the risk of complications.


